HALO
Valuation Score
View as %
Stock Unlock
1D
1W
1M
YTD
1Y
3Y
5Y
Max
Stock Profile
- Market Cap$7.50B
- IndustryBiotechnology
- EPS (TTM)$2.69
- P/E (TTM)23.67
- Div & Yield--
- FCF Payout Ratio--
- P/S (TTM)5.37
- P/B153.69
- Diluted Shares117.65M
- Ex-Dividend--
- Next Earnings05-04
- Forward P/E7.75
- Payout Ratio--
- P/FCF (TTM)21.03
- FCF Yield4.76%
- Earnings Yield4.22%
- 52 Week Range
Score Card
Explore Scores Tab
4.36
Very Good
Valuation Model
Key Score
2.00
Bad
Management
3.00
Average
Growth
3.00
Average
Profitability
1.00
Very Bad
Fin. Health
3.00
Average
Dividends
--
--
Analyst
1.00
Very Bad
Insider Transactions
Explore Insider Tab
Buy
Sell
Market News
Page 1 of 21
Annual & Quarterly Financial Reports, Current Reports/Updates, Ownership & Insider Transactions, Proxy Statements, Other
Form 3
Initial statement of beneficial ownership of securities - general instructions
Filed on 2026-03-23 18:35:07
Form ARS
Unknown Form Type
Filed on 2026-03-23 16:16:26
Form DEFA14A
Additional definitive proxy soliciting materials
Filed on 2026-03-23 16:13:32
Form DEF 14A
Also known as a 'definitive proxy statement', is a required filing when a shareholder vote is required
Filed on 2026-03-23 16:11:26
Form 8-K
Current report pursuant to Section 13 or 15(d)
Filed on 2026-03-12 08:32:00
Form 4
Statement of changes in beneficial ownership of securities - general instructions
Filed on 2026-03-10 19:18:55
Form 144
Notice of proposed sale of securities pursuant to Rule 144
Filed on 2026-03-10 16:05:17
Form 144
Notice of proposed sale of securities pursuant to Rule 144
Filed on 2026-03-09 16:18:04
Form 4
Statement of changes in beneficial ownership of securities - general instructions
Filed on 2026-03-04 18:56:16
Form 4
Statement of changes in beneficial ownership of securities - general instructions
Filed on 2026-02-24 18:19:02
Form 4
Statement of changes in beneficial ownership of securities - general instructions
Filed on 2026-02-24 18:16:08
Form 4
Statement of changes in beneficial ownership of securities - general instructions
Filed on 2026-02-24 18:14:46
Page 1 of 21
Financials
Explore Financials Tab
Revenue
Earnings
Free Cash Flow
Price Targets
Go to Analyst Tab
High:
$100.80
59.1%
Avg:
$86.19
36.0%
Low:
$56.56
-10.7%
Analyst Recommendations
Go to Analyst Tab
3.80
Good
13%
Strong Buy (2)
60%
Buy (9)
20%
Hold (3)
7%
Sell (1)
0%
Strong Sell (0)
About
- Website
- SEC Reports
- IPO Date2003-01-30
- IndustryBiotechnology
- Total Employees350
- ExchangeNasdaq Nms - Global Market
- Reporting CurrencyUSD
- GICSBiotechnology
- GICS SubBiotechnology
- GICS SectorHealth Care
- GICS GroupPharmaceuticals, Biotechnology & Life Sciences
Similar Stocks
Compare In Free Form
